Zosano Pharma (NASDAQ:ZSAN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Zosano Pharma (NASDAQ:ZSANGet Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, BTIG Research downgraded Zosano Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, February 23rd.

Shares of ZSAN stock opened at $2.65 on Tuesday. The company has a market cap of $12.84 million, a P/E ratio of -0.28 and a beta of 2.98. The stock has a 50 day simple moving average of $8.38 and a two-hundred day simple moving average of $15.81. Zosano Pharma has a fifty-two week low of $2.59 and a fifty-two week high of $37.45.

Zosano Pharma (NASDAQ:ZSANGet Rating) last issued its earnings results on Thursday, March 17th. The biotechnology company reported ($2.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.45) by $0.35. The business had revenue of $0.09 million during the quarter. Zosano Pharma had a negative return on equity of 80.12% and a negative net margin of 3,812.10%. On average, research analysts predict that Zosano Pharma will post -7.69 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZSAN. Citadel Advisors LLC increased its holdings in shares of Zosano Pharma by 263.9% during the third quarter. Citadel Advisors LLC now owns 146,166 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 105,999 shares in the last quarter. Barclays PLC increased its holdings in shares of Zosano Pharma by 50.0% during the third quarter. Barclays PLC now owns 300,000 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 100,000 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Zosano Pharma during the second quarter valued at approximately $65,000. Morgan Stanley increased its holdings in shares of Zosano Pharma by 954.9% during the first quarter. Morgan Stanley now owns 45,879 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 41,530 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Zosano Pharma by 95.7% during the third quarter. LPL Financial LLC now owns 58,700 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 28,700 shares in the last quarter. Hedge funds and other institutional investors own 10.57% of the company’s stock.

Zosano Pharma Company Profile (Get Rating)

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine.

Read More

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.